Amgen Inc., arguably the leader in protein-based drugs, is making sure that it participates in biotech's shift to medicinal chemistry through the formation of strategic alliances that bring in small molecule expertise.

AMGN's recent deal with Arris Pharmaceutical Corp. to discover and develop oral synthetic cytokine mimetics marks the second collaboration in the last six months